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INTRODucnON 
Posmansplant Iymphoproliferative disorders (PTLDs) are 
a fumily of lesions that Straddle the borderland between 
infection and neoplasia. The term PTLD is best used to refer 
to those lymphoid growths which occur in organ transplant 
patients and in which evidence of the Epstein-Barr virus can 
be demonstrated. Accordingly, PTLDs can be considered to 
represent phases of infectious mononucleosis which are rarely 
seen in immunocompetent hosts. Specifically, destructive 
lymphoid infiltrates. gross rumor formation and clonal prolif-
erations of lymphoid cells are major components of these 
progressive forms ofIM. In some cases, true malignancy may 
also occur. 
Our understanding of this disease advanced significantly 
during the 1980s when it was recognized many PTLDs could 
regress consequent to withdrawal of immunosuppression. I 
This knowledge cunaiIed the preemptive usc of chemo-
therapy in these disorders and focused later attention on 
biological response modifiers as possible therapeutic agcnts.2 
However, experience has also shown that a subset of rumors 
do not respond to such immunomodulation.3•4 A present 
challenge is to distinguish this subset of rumors, which may 
require antineoplastic chemotherapy, from the majority of 
PTLDs. which do not. 
PTLDs must be distinguished from sporadic lymphomas 
or non-EBV-associated lymphadenopathies which may also 
be seen in the transplant population. In this review the 
discussion focuses on those lesions in which the presence of 
EBV has been demonstratcd.5 Selected aspects of the EBV-B-
cell interaction and of host control mechanisms utilized 
during EBV infection are also considered, since these topics 
deal with the host-parasite system from which P'TLDs emerge. 
Additional EBV -rdated posttransplant rumors such as spindle-
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cell rumorb and Hodgkin's disease-like proliferations7 are 
briefly considered at the end of this discussion. 
NORMAL RESPONSE TO INFEcnON 
WITH EpSTEIN-BARR VIRUS 
Epstein Barr virus is a double-stranded, enveloped DNA 
gammaherpesviruswith a host specificity restricted to humans 
and nonhuman primates.s The virus is ubiquitous and infec· 
tion (or infestation) exists in 90% of individuals worldwide.9 
Approximately 100,000 cases of 1M occur annually in the 
United States. IO 
Active infection is most often initiated by salivary contact 
EBV may infect oropharyngeal epithelial cells via interaction 
between the external viral glycoprotein 350/220 and a CR2 
(complement receptor type 2)-like receptor on the host cells. I I 
The identity of this cellular receptor is a current issue of 
debate.11 Following cell penetration, the virus initiates a 
productive infection which in turn facilitates infection of 
recirculating B lymphocytes in this region. The oropharynx is 
considered to represent a major repository of the virus, and 
viral shedding can be detected in up to 100% of infected 
individuals with appropriate techniques. 13 However, one 
group has recently questioned this sequence of events. since 
they were unable to find evidence of lytic EBV infection 
within oropharyngeal epithelium during acute mononucleo-
sis by the usc of sensitive in situ hybridization procedures. 14 
The B-Iymphocyte EBV receptor (CD21) is also the 
physiologicCR2 receptor, and a receptor for the B-cell protein 
CD231s as well as for 1FN-n.16 Once within the B lympho-
cyte, the virus ultimately circularizes into an episomal form.8 
B-ceI1 proliferation and plasma cell differentiation follow. 
This induced behavior of infected B cells may be one source 
of antibodies. including autoantibodies, characteristic ofIM. 
Additionally, such antibodies may be due to antigenic simi-
larities between the virus and host.17•21 
The B-cell lymphoproliferation evokes a powerful host 
regulatory response. Studies have consistently shown in-
creased numbers of natural killer (NK) cells and cytotoxic 
(CD8+) Tcells during the carly stages of acute IM.22.l3 NKccl1s 
(large granular lymphocyres)14 mediate cell killing in a non-
HIA-rcstricted fashion and represent an important first line 
of defense. In one study the absence of these cells was 
associated with a more severe clinical course.2S However, 
another study found a transient decrease in NK funaion, 
62 TRANSPlANTATION SCIENCE September 1994 
despite increased nwnbers of these cells, at the time of acute 
1M diagnosis.Ui CDS· (suppressor/cytotoxic) T lymphocytes 
constitute the primary effeaor cell in this disorder.26 Both 
CD4· and CD8+ T-cell subsets express the activation marker 
CD45RO (UCHLl),27 but only CDS· T cells mediate 
specific cytotoxicity in an HLA class I-restricted fashion.28 
In some animal studies, noncytolytic CD4+ and CD8· T 
cells have been shown to be capable of causing regression of 
tumors. One study used activated cells from tumor-draining 
lymph nodes to prevent subsequent metaStatic disease in mice 
of the same strain inoculated with the same tumor. It was 
found that gamma-interferon (IFN-y) was an important 
mediator of this effea, apparently due to its antiproliferative 
activity. Further. this effea could be inhibited by antibodies 
to lPN-y. 
Earlier studies referred to the putative viral targets recog-
nized by cytotoxic T cells as LYDMAs (Iymphocyte-deter-
mined membrane antigens). More recent studies have shown 
that both EBNAs (EBV nuclear antigens) and LMPs (EBV 
latent membrane proteins) may serve as preferential targets, 
dependent upon host HLA typeK~ For example, cells derived 
from HLA-All + individuals preferentially react with experi-
mental target transfectants containing the EBNA 3b and 3c 
gene products. while they remain unresponsive to cells 
expressing EBNA 1.30 In contrast, HLAA2.1-positive cells 
preferentially recognize LMP2 and less frequently recog-
nize EBNA 3b.J1 Effective viral control is most likely 
maintained by recognition of different menus of viral 
antigens in different individuals. 
The T lymphocyte proliferation. which accounts in large 
part for the clinical "mononucleosis" associated with acute 
1M, is usually regarded as polyclonal or reactive to the B-cell 
process. In some cases a more restricted (oligoclonal) prolifera-
rion has been observed.32 This may correspond to restricted 
usage ofT-cell receptor subtypes (Vl36.1-3, s~TF which has 
been reported in one study of patients with acute IMY 
Increased expression of cells bearing y/O T-cell receptors 
has also been noted during this period.305 Such cells 
normally comprise only a small number of all T cells and 
ir has been suggested that they may help to mediate non-
MHC-restricted cytotoxicity.34 
Transient CUtaneous anergy can occur during acute infec-
rious mononucleosis.36 This may be related to the activation 
of suppressor T-cell activity during this stage of the diseaseY 
In addition. recent reports suggest that direct interference 
with T-cell receptor-mediated signals also occurs. In one study 
of cells from patients with 1M, signals delivered through the 
T-cell receptor pathway failed to result in normal T-cell 
responses despite normal reactions of these same cells to other 
forms of stimulation.J8 
The rapid expansion ofT cells ultimately abates as the acute 
inteaion subsides. This is mainly due to apoptosis. which 
occurs primarily in CD45RO· T cells according to one in 
vitro study. J9 These authors observed that the affected T cells 
could be rescued from apoprosis by the administration of 
imerleukin 2 Glr2), Ilr5 or Il.r6. but not llrl or llA. From 
this they suggested that continued local secretion of the 
appropriate cytokines in vivo might serve to maintain the 
viability of specifically reactive T cells. and that removal of this 
microenvironment would result in programmed cell death 
(apoptosis). 
A characteristic antibody response to EBV infection begins 
with production ofIgM antibody against the EB viral capsid 
antigen (YeA.). This isotype disappears rapidly and it is 
replaced by IgG anti-VeA. which remains elevated for life. 
Most patients also develop antibody to an antigen of the early 
lytic cycle, EA(D), for a short period of time. Antibodies to 
EBNA do nor develop until late in active infection but persist 
for life in routine cases. 10.1 I 
A variety of cytokines and other molecules undergo 
upregulation during acute 1M. IFN-y, IL-2 and Ilr I-a levels 
are elevated. as is neopterin, a marker of IFN-y-induced 
monocyte activation.40.41 Perf orin levels are also elevated in 
acute IM.42 Levels of this molecule may correlate to the extent 
of cytotoxic activity in vivo.42 No increases of fi-l-~K IFN-a, 
or IL-6 were observed in one study of acute IM.40 
Following control of the acute infection over a 1-3 month 
period, cytokine levels return to baseline. Around this time the 
infection enters a latent stage. Persistence of virus in both 
blood cells and oropharyngeal washings has been demon-
strated, but the relative importance of these sites as the main 
coffer oflarent virus remains to be determined. 43 The infection 
remains under the control of immunosurveillance mecha-
nisms of which cytotoxic T cells comprise the major effec-
tors." Cells with specificity for both latent and lytic EBV 
antigens persist in the host.44 
In some patients, a chronic active form of EBV can 
deveiop,45 characterized by prolonged or repeated bouts of 
viral symptoms of 1M. This may rarely culminate in a 
Iymphoproliferative disorder of large granular lympho-
cytes presumed to be NK cells.46 In one case EBV was not 
observed in the cells. but in a second case clonal EBV was 
detected, suggesting a causative role of the virus in this 
abnormal proliferation.47 
MOLECUlAR ASPECTS OF EBV-B CELL INTERACTION 
The major viral glycoprotein, gp350/220. interacts with 
the C3d receptor (CD21 .CR2) on the surface ofB Iympho-
cytes.8 These receptors are expressed mainly in resting B 
lymphocytes, and may have a role to play in the activation of 
these cells. 12 The viral glycoproteinlCR2 interaction may also 
contribute to activation of the alternative complement path-
way.48 In vitro infection can be inhibited by addition of soluble 
recombinant CR2, leading to the suggestion that this mol-
ecule may have therapeutic application in EBV infection.49•50 
The virus is then incorporated into the cytoplasm via 
endocytosis. Another viral glycoprotein. gp85. mediates fu-
sion with cellular endocytic vesicles and this process releases 
the virus into the cytoplasm. The virus may associate with 
vimentin and it is then carried into the nucleus. It circular-
izes and proliferates within the cell to exist as multiple 
episomal copies. 11 
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A limited number of viral gene products are expressed 
during latent infection. These include six EBV nuclear anti-
gens (EBNAs). two membrane-associated proteins (latent 
membraneproteinsorLMP1.2)andtwonontranSlated"early" 
RNAs (EBER 1.2).51 Many of these proteins interact to 
induce B-cell activation: EBNAs 2,3A,3C, LMP1 and EBNA 
LP have been shown to be essential for such tranSformation of 
the host cell.52 EBNA-2 up regulates a specific viral promoter 
(latency C promoter) which in rum leads to production of 
viral latent membrane protein (LMP 1). This molecule in rum 
upregulates production of vimentin,53 associates with this 
protein,54 and induces various surface proteins on the cell 
including the transferrin receptor and the adhesion markers 
LFA-l, LFA-3 and lCAM_1.55 Bcl-2, which protects the cell 
from apoptosis, is also induced. 56 LMP1 cooperates with 
EBNA 2 to increase expression of the B-cell activation marker 
CD23.57 Another membrane protein, LMP2A, colocalizes 
with LMPI and has been shown to diminish the calcium 
mobilization associated with cross-linking of B-cell surface 
immunoglobulins,5l The purpose of this is unknown; it 
has been suggested that it may serve to regulate EBV-
associated cell proliferation or it may diminish the likeli-
hood of lytic cycle induction. which is associated with 
increased intracellular free calcium. 51 
B-cell activation by the virus bypasses the normal cell 
membrane signaling pathway in which inositol phospholipids 
are cleaved. 58 EBV thus resembles the tumor-promoting 
phorbol ester TPA in this regard. 59 As a consequence, there 
is a decreased requirement for calcium in EBV-induced 
cellular DNA synthesis. 
The exact circumstances which determine whether an 
individual B lymphocyte will undergo blast transformation 
upon EB viral infection are unknown. Some studies have 
suggested that the resting B lymphocyte is the primary target 
cell which undergoes these changes. Crain et alGO provided 
evidence that in vitro EBV infection preferentially induces 
proliferation of those B cells which were already poised to 
rraversethecellcyde. TheyfoundthatBac-l,amarkerofearly 
B-cell activation, marked those B cells in which EBV 
intection led to a high proliferation rate. Later in the cell 
cycle, when surface IgD was lost. the cell responsiveness to 
intection declined. 
EB V-associated B-cell proliferation may also be dependent 
upon the presence of exogenous growth factors. Evidence 
mggests that lymphotoxin,61 IL_I,62 IL_5,63 IL-6,M 
Ihioredoxin,c5 and soluble CD2366 may all act as autocrine 
growth stimulators in this regard. In addition, monocyte 
derived products. including IL_667 may contribute to stimu-
lation of EBV-infected B-celliines in viero. In one study. a 
sYnergistic effect of recombinant IL-4 with supernatant from 
.lCtivated monocytes on proliferation ofEBV-transformed B 
cells was demonstrated.68 Not all investigators have obtained 
identical results. and Jocherns et al69 stressed the variability of 
differentEBV-infected B<d.Ilinesin both theproduaionand 
response to individual cyrokines. It is likdy that a similar 
panorama exists in vivo. 
Increased production ofIL-l 0 has been observed in B cells 
in vitro following EBV infection.70 The authors of this srudy 
reponed that this action enhanced the establishment of 
tranSformed cell lines. In addition, they suggested that this 
cyrokine might inhibit the antiviral response of the immune 
system in vivo. It is interesting that the form ofIL-l 0 found 
in these cells was the human and not the EB viral lL-10 
analog; the laner molecule is expressed during the lytic 
cycle of infection,?1 
Three forms of virus latency have been described. each 
expressing a different complement of viral proteins.72 The 
different latencies are trarIScciptionaily distinct. and use differ-
entviral promoter sequences. All infected cells express EBNA-I 
protein, which binds to DNA, is required for viral episomal 
maintenance and may also function to distribute the episomes 
during cell division,u In type 1 latency, which is seen in 
Burkin lymphoma cells, this is the only viral protein ex-
pressed.?3 This form oflatency utilizes the viral Fp promoter 
only.74 Latency Type 2 is seen inEBV-infectedReed-Sternberg 
type cells as well as in nasopharyngeal carcinoma cells and 
shows expression ofEBNA 1, LMP 1 and possibly LMP2.75 In 
this form the Fp promoter is again used and other proteins are 
expressed using their individual promoters. Latency type 3 
was initially described in vitro in EBV -infected lymphoblastoid 
cell lines and shows expression ofEBNAs 1-6 and lMPs 1 and 
2.72 In this case. F p is not used and one of two other promoters, 
Cp or Wp. are utilized in addition to specific LMP promot-
ers.74 All three types oflatencyalso express a high copy number 
of nontranslated, polyadenylated RNAs (EBERs)73 as well as 
other transcripts which likely play an important function in 
maintaining latency.76 Lymphoblastoid cells with type 3 
latency express a variety of B-cell activation markers, in 
contrast to down-regulation of these molecules in Burkitt 
lymphoma cells. Such down-regulation is thought to contrib-
ute to the ability of Burkitt cells to evade host T-cell 
imrnunosurveillance mechanisms. -:7·79 
An increase in intracellular calcium due to cell surface 
receptor cross-linking has been shown to be associated with 
the induction of the lytic stage of the viral life cycle in vitro.ao 
In addition, lytic infection has been associated with more 
mature stages of differentiation in both lymphoid and epithe-
lial cells.72.81.82 The switch from viral latency to productive 
infection is initiated by expression ofthe viral "Zebra" protein. 
which in turn trarISactivates other lytic cycle proteins. I I The 
lytic cycle results in production of mature viral particles and 
infection of additional cells within the host. Of the proteins 
produced during this phase of the viral life cycle. the major 
glycoprotein of the viral capsid antigen is particularly domi-
nant and leads to the production of neutralizing antibodies. 10 
Two different forms ofEBV isolates, termed EBV-l and 
EBV-2 have been described.s3 EBV-l strains are more effi-
cient than type 2 stains in their ability to transform lympho-
cytes in vitro. 83 Despite differences in several genes.54 itappears 
that differences in EBNA 2. which may reflect a recent 
evolutionary event-'s arc most important in conferring this 
adv:antage upon EBV-I strains.86 
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PATIiOLOGIC ASPECTS OF INFEcnOUS 
MONONUCLEOSIS IN LYMPHOID TISSUE 
The characteristic morphology of lymphoid tissue under-
going active EBV infection reflects the exuberant 
Iymphoproliferation which is a mechanism common to both 
the infection and its conuol by the host. In most cases, a 
recognizable paracortical expansion oa;ursB7 and total archi-
tectural effacement is not seen. This proliferation results in a 
population oflymphocytes ranging from small to large in size. 
Large, atypical cells with features of Reed-Sternberg cells have 
been described.s7 These celJs have been suggested to be the 
precursors of the true Reed-Sternberg cells of Hodgkin's 
disease88 and recent srudies have shown these cells to (a) 
contain EBV and (b) have phenotypes similar, but not 
identical to, Reed-Sternberg cells.88 However, the activated 
background precludes the diagnosis of Hodgkin' s disease and 
the exact relationship of these cells to cases of EBV-posirive 
HD remains problematic. Necrosis, increased prominence of 
postcapillaryvenules, and frequent mitoses also occur in acute 
IM.s7 One study applied in situ hybridization to show that 
EBV was present in occasional endothelial cells and sinusoidal 
lining cells in lymphoid tissue from patients with acute 
IM.89 In a separate study, in situ hybridization of tonsil 
sections from cases of acute 1M demonstrated EBV within 
interfollicular areas, bur viral presence within tonsillar 
epithelium was not found. 14 
We have recently applied in situ hybridization for EBER to 
a series of 100 unselected tonsils from children undergoing 
routine tonsillectomy. Twenty per cent showed evidence of 
EBV-positive cells and in 5% the frequency was substantial. 
I t is probable that these cases represent early infectious mono-
nucleosis. although a high viral carriage state cannot be 
excluded. These tonsils showed follicular hyperplasia with 
both randomly scattered paracortical EBV + cells and rare 
individual follicles in which the majority of lymphoid cells 
were EBER-positive (Y unis E and Nalesnik M., unpublished 
observations). Rare follicles with prominent EBER positivity 
have been recently reported in cases of acute IM.90 
In one study of normal or reactive lymph nodes obtained 
from nonimmunosuppressed patients in an area of high EBV 
infection. scattered EBV-positive T and B lymphocytes were 
seen in approximately 50% of cases.?1 This may reflect 
persistent latent virus in these patients and is not associated 
with any specific pathological changes. 
IATROGENIC IMMUNODEFICIENCY 
OF ORGAN TRANSPLANT PATIENTS 
To date. the goal of allograft-specific tolerance has not been 
met. and prophylaxis and treaanent of organ rejection rdy 
primarily upon blockade of lymphocyte activation. Within 
this context. different categories of drugs exert their effects by 
different means. Theoretically, these may impact upon the 
host:EBV interaction and lead to differing manifestations of 
PTLD. The difference in onset time between PTI.Ds occur-
ring under azathioprine regimens and those occurring under 
CsA or FK506-based regimens provides circumstantial 
evidence suggesting a more profound interference with EBV 
control mechanisms with the latter two drugs.92.?} Conversely, 
most posruansplant central nervous system lymphomas have 
been seen in azathioprine-based series. 94 The reasons for these 
apparent differences are unknown. 
CsA and FK506 are both considered to be prodrugs which 
acquire their immunosuppressive properties after binding to 
cytoplasmic immunophilins.95 Several isoforms of CsA-bind-
ing proteins (cyclophilins) and FK506-binding proteins 
(FKBP) are known, most having wide tissue distribution. The 
drug-immunophiJin complexes result in new functional com-
pounds with calcineurin-binding capability. Despite differ-
ences in their surface topographies, both CsA-cyclophilin and 
FKS06-FKBP complexes share this feature. 
Calcineurin is a Ca2. and calmodulin dependent phos-
phatase.%·97 Its activity is blocked by the drug-immunophilin 
complex and this obstruction may contribute to the immuno-
suppression induced by these drugs.96.97 Both CsAand FK506 
interfere with a nuclear factor of activated T cells (NF-AT), 
which is a transcription factor essential for expression of early 
T-cellactivationgenes.98 NF-AT consists of two subunits, one 
nuclear and common to many cell types, the other cytoplas-
micand presumed specific to T cells. It is hypothesized but not 
proved that this cytoplasmic factor requires dephosphoryla-
tion in order to be translocated to the nucleus and to combine 
with the nuclear subunit to form functional NF-AT. If one 
presumes that this dephosphorylation is directly or indirectly 
mediated bycalcineurinlcalmodulin, a logical siteofinterfer-
ence by CsA or FK506 is derived.99 
In keeping with this hypothesis, these drugs have also been 
shown to interfere with Ca"' dependent signals within B 
lymphocytes such as response to anti-immunogiobulins,lOo 
while largely sparing Ca"' independent responses such as those 
to lipopolysaccharide. IL-4,101 or EBV.102 
Azathioprine (Imuran) is a 6-mercaptopurineanalogwhich 
is cleaved in vivo into its active form. thioinosinic acid. 103 The 
latter interferes with purine biosynthesis and leads to de-
creased cell-mediated hypersensitivity. This drug has been 
associated with some apparently temporary chromosome 
abnormalities in humans. 103 
Glucocorticoids bind to cytoplasmic receptors and are 
then transported into the nucleus where they affect gene 
transcription and inhibit lymphocyte proliferation. IL-2 and 
IL-I production have been shown to be down-regulated by 
these compounds. I04 
o KT3 and related antibodies block T-cell cytotoxicity by 
interfering with the interaction between CD 3 and the T-cell 
receptorKll~ Following initial administration. a cytokine re-
lease syndrome can occur, characterized by increases in circu-
lating TNF-a. IFN-y, IL_6,106 and IL-l 0. 106 
EBV INFEcnON IN TRANSPUNT PATIENTS 
Ho et al l07 demonstrated a 77% seroconversion rate in 
pediatric liver transplant patients who were seronegative for 
EBV at the time of transplant. Seropositive patients demon-
strated evidence of posttransplant reactivation infection in 
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48% of cases. In both instances the mean onset time was 60 
days posttransplant. In adult recipients of solid organs primary 
posttransplant infection occurred in 82% and reactivation 
infection in 33% of cases. Yao et aP08 demonstrated that the 
salivarysheddingofvirusisincreasedinEBV-positivepatients 
following immunosuppression for renal transplantation. Their 
data suggest a relationship between pre- and postimmuno-
suppression viral shedding load, i.e., there may be constitu-
tionally "high" and "low" shedder status. PreiksaitislO9 dem-
onstrated increased oropharyngeal shedding ofEBV after the 
first posttransplant month in hean or kidney allograft recipi-
ents. Patients with primary infection shed more virus than 
those who were seropositive at the time of transplant, and 
hean transplant recipients had higher levels of peak shedding 
than did renal allograft patients. High-dose intravenous acyclo-
vir or ganciclovir eliminated detectable shedding, but shed-
ding again roseto previous levels after the drugswere stopped. 109 
The donor organ itself may be the source of EBV infec-
tion.IIO.1l1 In the elegant Study ofCen et al,m a single organ 
donor provided a kidney to one patient and ahean-Iung block 
to another. One recipient was seronegative before transplant 
and had serologic evidence of primary posttransplant infec-
tion. The seropositive patient had evidence of "reactivation" 
intection. Both patients developed PTLDs in their allograft 
organs. However, the identity of the virus isolated from the 
tumors was that of the donor in both instances. This 
suggests that some reactivation infections in organ trans-
plant patients may actually represent new primary infec-
tion with a separate EB virus and this virus may be 
responsible for PTLD development. 
The method of detection ofEBVis important. Marchevsky 
ct all 13 llSed peR to detect EBV in allograft lung biopsies. 
Despite the presence of the virus by this technique, several 
patients had histologic evidence of acute cellular rejection and 
responded to treatment for the rejection. This underscores the 
fact that EBV infection persists for life and that sensitive 
techniques such as PCR may detect EBVeven in those cases 
in which the virus is clinically irrelevant. Such a situation 
is not unexpected, since nonimmunosuppressed EBV-
positive individuals carry the virus in 1 in 105 to 106 B 
lymphocytes and the theoretical sensitivity of PCR ap-
p roaches 1 copy in 106 cells. 10 
Serology has usefulness in the evaluation ofEBV infection, 
but the transplant population may show atypical or absent 
antibody patterns. IO•11 In particular. diminished antibody to 
EBNA may be observed despite persistence of anti-VCA.114 
Howard et alii) have stressed the importance of risinganti-EBV 
ti ters in the particular situation of suspected rebound rejection 
following 0 KT3 use. In this scenario, continued anti rejection 
therapy could have disastrous consequences. 
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Frequency and Risk Factors 
PTLD frequency has generally been reported as the total 
number of affeaed patients divided by the total number of 
transplant patients for a given period of time. This caladation 
can only provide an approximation of the true risk of disease 
since (a) it does not censor patients who die from other causes 
and thus overestimates the number of patients atrisk, and (b) 
it does not calculate the actuarial risk of developing PTLD 
over time. Raw figures from our series have yielded annual 
PTLD frequencies of approximately 2.2%. Of these, the 
frequency is 1.0% for renal transplant patients, and 3.3, 2.7 
and 3.8% for recipients ofhean, liver, and hean-Iung trans-
plants.116 Several PTLDs have also occurred in recipients of 
small bowel or multivisceral organ allografts at our institution. 
Bone marrow transplant recipients have a very low frequency 
of PTLDs unless HLA-mismatched, T-cell-depleted al-
lografts are used, in which case the frequency approximates 
24%.117 Chao et alliS reported a unique case in which 
fulminant PTLD developed in a recipient of autologous 
bone marrow. 
Artnitageetal"9 re-examined the cardiothoracictransplant 
population at our institution. After removing patients who 
did not survive past 30 days posttransplant from consider-
ation, they calculated a 3.4% frequency ofI>TLD in heart, and 
7.9% frequency in lung recipients. 
Malatack et al l20 examined a cohort of 132 pediatric liver 
allograft recipients from the Pittsburgh series and found the 
actuarial risk of developing PTLD to be 2.8% per year. This 
stabilized at a cumulative risk of approximately 20% by 7 
years, although the study was ended shortly thereafter. 
Sheil'21 analyzed the Australia and New Zealand renal 
transplant population and found that lymphomas constituted 
40% of all nonskin malignancies after 10 years but only 12% 
after 20 years. This was due to the late occurrence of other 
types of cancer in this population. His data showed that 64% 
of patients had some form of malignancy after 20 years and 
that cancer accounted for 34% of deaths in patients with 
functioning grafts after 10 years. 
The duration of immunosuppression, dosage of the agents 
used, and the number of agents used have all been felt to 
contribute to the risk of posttransplant lymphomas. including 
PTLDS.I22 Recently, an increased risk ofPTLD was found in 
one series when prophylactic OKT3 was used in hean trans-
plant patients in conjunction with triple therapy consisting of 
cyclosporine, azathioprine, and prednisone. Cumulative doses 
of 0 KT3 under 75 mg were associated with a 9.2% frequency 
ofI>TLD, whereas doses in excess of this figure were associated 
witha37.5% frcquency.I23·124 Others have suggested thattotal 
immunosuppression rather than a single drug may be a more 
relevant factorKf~~ Alfrey et al l26 have observed early and 
aggressive PTLD which they telt was associated with 
antirejection OKT3 use in their series. We have not observed 
an increased incidence ofPTLD as a complication of prophy-
lactic OKT3 use in our cardiac transplant series. 
Primary EBV infection is also associated with a higher 
frequency of PTLD than is reactivation infection. Ho et 
alI07.127 documented a 10.5% frequencyofPTLD in a series 
of 95 seronegative children who had a primary EBV 
infection following tranSplanL This compared ro 0% fre-
qucncyin seropositive children with reactivation infection. 
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Corresponding figures for seronegative and seropositive adult 
recipients in this series were 4.9% and 1.6%.107.lZ1 
Preiksaitis et al109 have shown that patients who subse-
quently develop PTLD have a higher antecedent viral load 
than those who do not. Randhawa et all28 demonstrated that 
EBER positivity was demonstrable in 71 % of liver biopsies 
taken from patients who subsequently went on to develop 
pnD. This may reflect a higher viral load in these patients; 
however. this retrospective study needs to be supplemented by 
prospective studies in order to determine the predictive value 
of this approach. 
Clinical Manifestations 
The rime from uansplant to onset ofPTLD was analyzed 
in a series of renal transplant patients treated with an 
Azathioprine-based regimen.94 In these patients. two types of 
presentations were seen. The first resembled infectious mono-
nucleosis and occurred an average of 9 months after trans-
plant. The second presentation was that of a localized tumor 
mass. seen on average after 6 years posnransplant. 
In our cyclosporine-based series. clinical presentations 
included (a) an infectious mononucleosis-like syndrome with 
variablelymphadenopathy, (b) allograft dysfunction, (c) solid 
rumors, often of extranodal sites. or (d) fulminant dis-
ease.3.93.107.119.120.12'1 
The time interval between transplant and PTI.D was 
reduced in our patients relative to non-CsA-treated patients 
and the median time to onset was 4.4 months.3 Although 
many of the early lesions resemble 1M. this is not invariably the 
case. Late PTI..Ds also occur in our patients and these typically 
are localized rumors. Others have also noted earlv and late 
onset pnDs and have stressed the worse progno~is of late-
arising rumors. 1 19.130 
Patients with infectious mononucleosis-like SYndromes 
may have a preceding lymphopenia for variable nn;es. At the 
rime of clinical presentation, atypical lymphocytosis may be 
observed. Cervical lymphadenopathy and tonsillitis are typi-
cal and may be life-threatening. Some patients also have 
generalized lymphadenopathy and may have a maculopapular 
skin rash. 
Allograft dysfunction often raises the clinical suspicion of 
rejectionJ·115 and may present as tenderness over the involved 
site. often with fever. Lymphadenopathy may be present or 
(he allograft may be affected in an isolated fashion. 
Solid tumors may be single or multiple. They most 
commonly occur in excranodal locations and frequently 
involve the gastrointestinal tractll9.131 or allograft organ.93.119 
Particularly in the gut, rapid tumor growth may lead to 
considerable morbidity due to perforation. Skin involve-
ment is an uncommon but recognized form of this disorder 
and may occur in isolated form (Lee E. et al, in prepara-
tion). Involvement of the CNS usually takes the form of 
solid tumors, but a meningeal infLltrate with CSF pleocytosis 
may also occur. 
A leukemic piaure has been described in some patients.93 
This appears to represent an unusual and advanced form of 
this disease. The exact relationship of this to the more 
common forms of PTLD remains undefined. 
Occasional patients present with systemic signs and symp-
toms due to widespread lymphoproliferation.12o This may 
present as or evolve to multiorgan disease leading to 
multiorgan failure. Individual tumors occur in multiple 
sites and lymphadenopathy is common. These patients 
differ from others in that they tend to have concurrent 
opponunistic infections. perhaps reflecting a profound 
immunosuppression. 
Pathology 
The histologyofI>TLD reflects the lym phoid proliferation 
associated with EBY infection and the modification of this 
proliferation by an impaired host response. 
A range of mononuclear cell forms was observed in tissues 
from a series of five renal transplant patients who developed 
lymphoid tumors following transplantation. 5 This prompted 
the introduction of the term "polymorphic" to distinguish 
these growths from other forms oflymphoma. Two forms of 
polymorphiclymphoidgrowths, termed polymorphic diffuse 
B-cell hyperplasia and polymorphic B-cell lymphoma were 
observed. Both contained a mixture of large and smalllym-
phoid cells and differed from other reactive lymphoid 
conditions by the presence of tissue invasion. The poly-
morphic lymphomas also contained areas of necrosis and 
large immunoblasts with atypical features ("atypical 
immunoblasts"). It was noted that such cells could re-
semble Reed-Sternberg cells. 
The clinical courses of these patients could not always be 
inferred from a histological perspective.5 For instance, one 
patient with polymorphic hyperplasia died with disseminated 
disease, whereas another patient with polymorphic lymphoma 
was alive at four months following a reduction of immuno-
suppression and administration of Acyclovir. Additionally. 
one patient with polymorphic hyperplasia was found to have 
a cytogenetic abnormality within the lesion. Despite this. she 
was alive 26 months thereafter, following a temporary reduc-
tion of immunosuppression. 
We found a similar inability to precisely distinguish the 
clinical behavior of PTLD patients based on these histo-
logic features, and felt that the polymorphic nature of the 
infiltrate was the predominant histologic feature of note.3 
Although necrosis and atypical immunoblasts were ob-
served in individual cases, such patients in our CsA-treated 
series did not behave differently than those who lacked 
these features. In contrast, a smaller subset of patients had 
tumors which lacked the polymorphism found in the 
majority of patients. These "monomorphic" tumors most 
closely resembled non-Hodgkin's lymphomas and ap-
peared to augur a poorer prognosis. Hence our approach 
stressed the distinction between polymorphic and mono-
morphic PTLD and did not incorporate the term 
"lymphoma" into either category. Craig et aP32 have also 
recently commented on the usefulness of this simplified 
approach. 
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Over time, additional histologic categories were intro-
duced into the literature to accommodate patient specimens 
which could not be included within existing categories. For 
example, atypical lymphoid hyperplasia was the term applied 
to cases in which a polymorphic lymphoid proliferation was 
observed within the paramrtex oflymph nodes, but in which 
invasion characteristic of polymorphic hyperplasia or poly-
morphic lymphoma was not observed. 133 Atypical polymor-
phic B-cell hyperplasia was used for cases with featureS 
intermediate between polymorphic hyperplasia and poly-
morphic lymphoma.133 We introduced the term "minimal 
polymorphism" to refer to those lesions in which a minor 
degree of variability was scm among benign-appearing cells of 
plasmaceUular appearance.l Others, however, have observed 
pure plasmacytic differentiation ofPTLDs in extranodal sites 
such as skin or testisl34 and have considered these lesions to 
most closely resemble plasmacytomas. 
In retrospecr, the main achievement of these classifications 
has been to recognize that posttransplant lymphoproliferations 
associated with Epstein-Barrvirus are fundamentally different 
from sporadic non-Hodgkin's lymphomas. Some cases are 
hisrologically identical to infectious mononucleosis, while 
others show exaggeration of individual features, such as 
necrosis or Reed-Sternberg-like cells, that may be seen in 1M. 
Most monomorphic tumors and tumors with a predomi-
nance ofReed-Sternberg-likc cells (or atypical immunoblasts) 
probably represent the emergence of neoplasias resembling 
non-Hodgkin's lymphomas or Hodgkin's disease, respec-
tively. Beyond that, the emphasis on histopathologic subclas-
sification diverts attention from the fact that these lesions are 
primarily manifestations of uncontrolled or poorly controlled 
infectious mononucleosis. In this regard, it may be impossible 
to set a dividing line between "infectious mononucleosis" and 
"PTID" in the tranSplant patient. Many histologic features of 
rTIDs can be seen in 1M. In addition, involvement of solid 
organs may occur in 1M, raising the question of distinguishing 
between 1M and PTLD at these sites as well. 
For instance, EBV hepatitis in the transplant recipient may 
be histologically similar to that described in immunocompe-
rent patients.13W6 The presence of nodular masses, usually 
beginning in portal tracts, and associated with atypicallym-
phoid cells, merits the diagnosis of PTLD in our opinion. 
There is, however. no sharp histologic cutoff point between 
these two diagnoses. 
In the kidney, P11..D may present as an infiltrative or 
tumorous lesion with a similar nosological dilemma. 
Gut lesions present as ulceronodular masses of 
Iymphoproliferation which appear to begin in the submucosa 
md rapidly infiltrate the entire wall. The use ofEBERstaining 
has allowed the detection ofEBV within a Peyer's patch in an 
otherwise normal bowd biopsy in one of our patients. indicat-
ing that a presendy unappnriated subclinical latent infection 
may also exist in this organ. 
In the skin, epidermal and adnexal necrosis may occur. 
Deep dermal infiluation dwacteristic of other lymphomas is 
observed and atypicallympboid cdls may be seen. 
CNS lesions are rare in our series,137 despite the known 
association between EBV and eNS lymphomas in 
immunocompromised patients.138 
PTI..Dinlungsissuspectedwhensignificantplasmacellular 
infiltration is found in this organ. The lesions tend to present 
as multiple nodules. P11..D of the allograft heart isc:xceedingly 
rare but does occur (personal observations). The process 
resembles Grade 3-4 rejection but with frequent blast cdls and 
plasmacytic infiltrate. An association between EBV and 
Quilty lesion has been postulated. but we have not found 
evidence of this in our series. We consider the differential 
diagnosis of Quilty lesions and endocardial-based rejec-
tion to be of more imponance. 
In closing. we believe that the distinction of "lM" from 
"PTLD" is ofless clinical importance than is the distinction of 
those growths which will from those which will not respond 
to host immunomodulation with supportive surgical inter-
vention. In our opinion. tumor monomorphism or abun-
dance of Reed-Sternberg-like cells or atypical immunoblasts 
remain the major histologic criteria which suggest a poor 
response to this therapy. Areas of monomorphism within 
otherwise polymorphic lesions and the presence of rare large 
atypical cells remain of questionable significance at present, 
since both of these features mav be seen in 1M in 
nonimmunocompromised patients. 
Phenotypic Analysis of PTLDs and In Situ Detection 
of Epstein-Barr Virus 
Studies have shown that the B-cell phenotype ofP11.Ds 
resembles that of EBV-infected lymphoblastoid cell lines 
rather than that ofBurkitt lymphoma. 139 Thus, expression of 
various EBNA proteins. latent membrane protein, and cell 
adhesion molecules ICAM-l, LFA-l and LFA-3 were ob-
served in these Studies. However, not all cases demonstrated 
the presence of all antigens tested. This may represent a 
technical artifact or it may indicate that P11.D cells are not 
stricdyequivalent to in vitro lymphoblastoid-celllines. Cen et 
al provided recent data to show that PTIDs downreguJate 
EBNA-2 expression and that they also show a variable iMP 
expressionv~ It is tempting to speculate that residual host 
sdection pressure may favor growth of clones in which an 
optimal profile of protein expression produces the maximum 
degree of cell proliferation with the minimum amount of host 
cytotoxic recognition. In this regard Alfrey et al l26 found 
evidence to suggest that good DR matching was a risk 
factor for the development ofPTLD. They hypothesized 
that expression of identical HLA rypes on proliferating B 
cells might similarly allow the cells to evade immune 
surveillance mechanisms. 
The past decade has seen significant advances in our abiliry 
to detect EBV genes and proteins within routinely processed 
pathologic specimens. First-generation detection kits utilized 
in situ hybridization with probes to internal repeat portions of 
the EBV genome. The use of probes to high copy number 
EBV RNA (EBER)I40 along with the development of rapid 
tissue hybrid.i:z.:Won protocolsl~1 has increased the usefulness 
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of this assay in the clinical setting. In addition, several com-
mercial suppliers provide antibodies to EBV latent membrane 
protein which can be applied to routinely processed tissues. 
We have found that microwave pretreatment of tissue also 
allows the application of anti-EBNA 2 antibodies to paraffin 
sections. In practice, we use anti-IMP 1 antibodies to detect 
EBV in clinical specimens and we support this with in situ 
hybridization for EBER when necessary. 
Studies at our institution show significant numbers of 
infiltrating cells within PTLDs (WU T et al, MS in prepara-
tion). These cells appear to be more frequent in polymorphic 
than in monomorphic cases. Combined phenotypic and 
EBER staining allows the distinction between infected and 
noninfected cells. We have found CO 3 + cells are generally free 
of EBV markers in the cases studied to date. In addition, 
~ignificantn~berofmacrophagesarepresentwithinmqils 
In our expenence. 
Infected cells usually carry B-cell markers. In most cases, 
C030' cells are extremely rare. The only exception is a case 
resembling HO, in which large EBER' cells were COtS', 
LeuM 1'. LNl+,LN2"C030+,EMk,LQ\",aphenorypewhich 
resembles that of RS celIs.7 COtS' cells are rarely seen in 
PTLOs except near areas of necrosis. 
Molecular Biologic Analyses of PTLDs 
Clonal Studies 
The polyclonal (reactive):monoclonal (malignant) di-
chotomy has been replaced by molecular studies which have 
demonstrated a gradation of clonal alterations within 
PTLOS."·142 These studies are largely based upon the behavior 
of immunoglobulin genes, which rearrange uniquely within 
the maruring B cell. All progeny of a B cell which has already 
rearranged its immunoglobulin genes will. by and large. carry 
that same rearrangement. This characteristic is exploited to 
detect clonal and nonclonal populations of B lymphocytes. 
Using these techniques, it has been shown that PTLDs can 
either be polyclonal (reactive) or they may contain clonal 
components which may comprise a small to large proportion 
of the cell population. We have graded these clonal compo-
nents as l' to 3 .. based on relative proportion, and have found 
some correlation with PTLD behaviorK~ Lesions with no 
evidence of gene rearrangements are felt to represent virus-
induced hyperplasias, despite the fact that some may show 
invasive tendencies. PTLDs with major clonal components 
were telt to indicate active neoplasia and were less likely to 
regress tollowing a reduction of immunosuppression. Con-
versely, those lesions with a minor clonal subpopulation 
presumably reflected either an emerging tumor ora clone with 
;l restricted growth potential." 
It has also been demonstrated that multiple concurrent 
PTLOs may each have unique clonal rearrangements.4•143 
This suggests an environment which facilitates the outgrowth 
of selected B lymphocytes. ora tendency for small numbers of 
B cells to spontaneously proliferate. We prefer the term 
.. clonal" PTLD over "monoclonal-PTID inon:iertodcsaibc 
this condition. Altem21eterms for this phenomenon include 
oligoclonalor multiclonal PTLDs. We prefer the term "mono-
clonal" for (a) a single tumor comprised primarily of one clone 
of cells, with no evidence of tumor elsewhere. or (b) multiple 
rumors, each with an identical clone of cells as demonstrated 
by immunoglobulin gene rearrangement analysis. In a prac-
tical sense, a monoclonal rumor is a fully developed neoplasm 
with a tendency to produce metastatic disease. Multifocal 
clonal disease may represent multiple, potentially reversible 
clonal outgrowths facilitated by the disordered physiology 
consequent to the interplay between virus infection and 
immunosuppression. 
In addition to these clonal patterns. some PTLOs may have 
evidence of more than one clone of cells within a single 
rumor.4.143 The terms oligoclonal or multiclonal PTLO have 
also been applied to this type oflesion. 
In the usual PTLD. rearrangements of the T-cell receptor 
cannot be found. However. individual cases of T-cell 
posttransplant rumors have been described.144.14s and in these 
cases T-cell rearrangements are seen in the absence of immu-
noglobulin gene rearrangements. 
Viral Analysis 
Using molecular probes for specific viral sequences, it has 
been found that almost all abnormallymphoproliferations in 
transplant recipients contain EBV. This has led us to use the 
term "PTLO" synonymously with "EBV-associated 
posttransplant lymphoproliferative disorder" and we consider 
any EBV-negative lymphoproliferation in these patients as 
representative of a different syndrome. 
Certain features of the virus allow srudv of additional 
variables. Probes to the viral terminal repeat region can 
distinguish active infection. in which the termini are nonfused. 
from latent infection. in which the episomal virus demon-
strates joining of the two terminal regions. Hu Further, when a 
single virus fuses its two terminal ends to produce the episomal 
form, a fixed number of terminal repeat segments are retained. 
and some are lost. This number may vary among different 
individual virus particles in a single infection. However. all the 
progenyepisomes that derive from a single episomal virus will 
retain that same number of terminal repeat segments.l46 
Hence, in a manner analogous to the evaluation of immuno-
globulin gene rearrangements. it is possible to determine a 
"polyclonal" from a "monoclonal" population of viruses 
within a given specimen.146 
This fearure has been used to analyze the question of 
whether a single virus is present ~t the initiation ofPTLD. or 
whether the cell proliferation provides a desirable target for 
viral superinfection. In the former case. a single clone of cells 
would be expected to carry a single clone of vi rus. In the latter 
case, one clone of cells may contain multiple viral forms. The 
results indicate that the virus is present prior ro the develop-
ment of PTLD. providing further evidence tor the impor-
tance of this virus in the development ofPTLO." 
It is generally assumed that latent virus infection pga~ a 
major role in this discxder. We· detected linear, repJ ....... 
EBV in a minorityofP11.DsusingSouthem blot proa:dma. 
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Subsequently, Katz et al147 examined a series of 13 patients 
with EBV lymphoproliferations occurring under a variety of 
immune deficient states, indudingorgan transplantation, and 
they found evidence of replicative virus in 40% of lesions. 
Recent in situ hybridization Studies have shown lytic tran-
scripts in 21 of22 PTIDS.148 
Cytokine Analysis 
Cytokines provide one major mechanism by which cells 
"talk" to one another. Like individual words, each cytokine 
has its own identity. However the "language" of cells com-
bines these words into sentences which can impose different 
contexrual messages superseding the isolated definitions of the 
component struCtures. 
Two such" sentences" are constituted by separate combi-
natorial patterns of cytokines referred to as Th 1 and Th2.149 
These patterns, originally defined in mice, reflect microenvi-
ronments conducive to providing help for cytotoxic T-cell 
activity (Thl) or for primarily B-cell-mediated immune 
responses (Th2).150 The Thl pattern is characterized by 
upregulation of IL-2, IL-3, GM-CSF, and lymphotoxin, 
while the Th2 environment shows the presence ofIL-3,lL-4, 
IL-S. IL-G. IL-I0, and GM-CSF.149 It has recently been 
demonstrated in a model system that IL-12 (NK-cell stimu-
latory factor), which is produced by macrophagcs, can shift 
naive T cells to a Th 1 pattern. lSI IL-4 effectively pushes cells 
into a Th2 pattern,152·153 and both IL-4 and IL-I0 can inhibit 
I L-12 production by human monocytes. l54 
Shapiro et al2 analyzed 5 bone marrow transplant recipients 
lor the presence of markers of Thl versus Th2 cytokine 
patterns in serum. Their results support the presence of a Th2 
l'!wironment in these patients. These authors have recently 
l'xp:mded their series to include 4 patients with solid organ 
transplant and PTLD, with similar results. 155 Burke et al l56 
reported a sequential rise of IL-2, followed later by IL-4 
L"lcvation and loss of detectable IL-2, in a patient with 
disseminated PTLD. 
We have recently looked at PTLD specimens themselves 
lor mRNA messages encoding IL-4 and cellular IL-I0 as 
markers ofTh2 and messages for IL-2 and IFN-yas indicators 
ofTh 1 starus (Nalesnik, M. etal,submitted). In every case the 
microenvironment was consistent with a Th2 pattern, sug-
gesting that these signals playa role in sustaining B-cell growth 
,md proliferation. I n addition. T osatO et all 57 recently reported 
t he presence of IL-6 in cells derived from these tumors and 
,howed that produaion of this cytokine was dependent upon 
(he presence ofadherent, non-B cells, probably macrophages. 
Karyotypic Studies 
Available data suggest that no single pattern of clonal 
brvorypic abnormality is seen in PTLD. Individual tumors 
may have a normal genotype or may contain unique cytoge-
netic anomalies. One study of six patients showed such 
.lbnormalities in three cases.ISl Two of these patients had 
polyclonal dise2SC by phenotypic analysis. and the latter had 
monoclonal disease by this method. Immunoglobulin gene 
analysis of clonality was not performed. Had this methodol-
ogy been available at that time, it may be that minor clonal 
populations would have been detected in the two polyclonal 
rumors. Two other patients had polyclonal disease and a 
normal karyotype. Finally, one patient had a normal karyo-
type in cells from two separate rumors, one polyclonal and one 
monoclonal. These data suggest that in some cases ofP11.D 
clonal outgrowth may be possible without corresponding 
cytogenetic abnormalities. 
In our series, one patient with a monomorphic P11.D 
demonstrated a t(8;14) in conjunction with other clonal 
cytogenetic abnormalities.4 The rumor was monomorphic 
and was recalcitrantto therapy, although it remainedloc:a1iz.ed 
for several years before leading to the death of the patienL This 
rumor also represented one of three specimens that demon-
strated c-myc gene rearrangements.' Karyotype analysis was 
not available for the other two specimens. 
In situ hybridization with chromosome specific probes has 
provided an alternative means for karyotypic analysis in recent 
years. In some instances, archival paraffin-embedded materi-
als may be used. We have found one example of a heavily 
chimeric PTLD by this method. The patient, a female liver 
transplant recipient received her allograft from a male donor. 
She later developed an EBV-positive PTLD in an axillary 
node. Approximately 10% of cells within the rumor displayed 
a male phenotype, as demonstrated by in situ hybridization 
using a fluorescent probe specific for a portion of the Y 
chromosome. Other PTLDs have shown extremdy rare 
donor cells in sex-mismatched cases (Nalesnik, M. and 
Demetris. A., unpublished observations). This is compatible 
with the concept of chimerism as recently demonstrated in 
solid organ transplant recipientsi59-ICA :lnd in our opinion is 
not a finding specific to PTLOs. There may be an intersection 
in some cases between acute GVHO and PTLD which 
remains to be defined. 
In a different vein, Spiro et all 65 used PCR analysis of 
DNA polymorphic loci to conclude that a lymphoma 
occurring in the porta hepatis of a transplanted liver was of 
donor origin. The authors did not comment on EBV 
involvement in this case. 
Prevention and Treatment of PTLDs 
Minimization of immunosuppressive therapy and pro-
phylactic use of antiviral drugs represent a rational approach 
[Q reducing the risk of PTLO development. Unfortunately, 
neither of these measures are entirely etfective or even possible 
in individual cases, and a high level of suspicion for this 
disorder remains essential. It is likely that other unknown 
factors may impinge upon the virus:host interaaion. For 
instance. one randomized study of nonimmunosuppressecl 
1M patients found that those treated with aspirin acrually had 
a more prolonged disease course than those given placebo.l66 
It is possible that such observations may provide hints appli-
cable to the transplant population as well . 
Vaccination against EBV might represent a means of 
preventing PTLD by eliminating the major factor 
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predisposing to this condition.l67 As such. it would be 
expected to prove most useful in the pediatric population. 
since these patients are more often seronegative at rime of 
transplant. It is also possible that a vaccination of seropositive 
patients may serve to boost immunity to the virus. leading to 
lower viral burden posttransplant and a lower risk ofPIID. 
However. this remains highly speculative at present. 
Several vaccine preparations are under evaluation. Most 
target the major envelope glycoprotein which inter.lCtS with 
the cellular EBV receptor.l67 Epstein et all68 have shown that 
vaccination of nonhuman primates prevents lymphoma for-
mation upon subsequent challenge with EBV. Phase I trials 
may begin within 1-2 years if current trends continue. 
Reduction oftmmunosuppression togetherwithAcyclovirl 
Ganciclovir and surgical management of complications re-
mains the mainstay of therapy for PTIDs. The overall rate of 
total remissions in PIID cases has been reponed to approxi-
mate 31 % in a composite series of323 patients. according to 
the Cincinnati Transplant Tumor Registry. 169 Responses may 
be dramatic over several days. or may proceed more slowly 
over 1-2 months. (In 1M in nonimmunosuppressed individu-
als.lymphadenopathy for more than 1 month is unusual). 170 
The time course for evaluation of the efficacy of reduced 
immunosuppression is influenced by the clinical condition of 
the patient. A mild degree of rejection may be tolerated, but 
this must be balanced against the need to assure continued 
function of a vital organ such as the hean. Malatack has 
recendy oudined the approach of his group to the issue of 
reduced immunosuppression.12o Following resolution of the 
disease. we usually retiter immunosuppression to maintain 
stable allograft function at the lowest level of drug. Others 
have reponed switching from CsA. to Azathioprine-based 
immunosuppression. also with acceptable allograft mainte-
nance.171 R.etransplantation is also possible.172 
The utility of antiviral medication in these patients is 
unclear. In acute 1M, the use of acyclovir results in a 
temporary marked reduction of salivary viral load. but has 
no effect on peripheral blood cell virus load.173 Occasional 
transplant patients at our institution have developed PTLD 
despite the use of prophylactic antiviral therapy(M. Green, 
personal communication). Nevenheless, recent evidence 
of a lytic component of virus within PTLDS4.141 suggests 
that these drugs may have some efficacy in preventing 
continuing infection. 
The major complication associated with reduced immu-
nosuppression is organ rejection. At present, there is no way 
to predict who will and who will not reject their allograft. 
Whereas some patients exhibit a vigorous rejection response, 
others never require reinstitution of immunosuppression. In 
our patient population, those with PTIJ) appear to be 
d is proportionally represented among those who have succcss-
fully bcen weaned from immunosuppressive medication (Reyes 
G. et al, MS in preparation). However, it is not known 
whether this is related. to the pathophysiology of this di.sea.sc or 
represents a sdea:ion an:i&adue to the universal reduaion of 
immunosuppression in this population. 
Active immunomodulationhas been attempted by admin-
istration of cytokines in selected patients. Shapiro et al2 used 
IFN-a together with intravenous immunoglobulin in 5 
patients with EBV-associated lymphoproliferations. Two of 
these patients had received bone marrow transplants and the 
other three had constitutional immunodeficiencies. One 
posttransplant patient each had. monoclonal or polyclonal 
disease. Both underwent complete remission, although the 
patient with monoclonal di.sea.sc expired several weeks there-
after due to CMV infection. In a more recent report. this 
group reponed partial to complete remissions in 4 evaluable 
immunoddlcientpatientswithEBV-associatedtumoIStreatcd 
with recombinant IFN-a alone. ISS Successful use ofIFN-a 
and intravenous immunoglobulin in PTLD following bone 
marrow transplant has also been reponed in two cases by Trigg 
et al. 174 Other cyrokines, such as TNF a, may also have a role 
to play in future immunomodulation of these lesions.l75 
Fischer et all76 reponed on the usefulness of monoclonal 
antibody therapy using a combination of antibodies to CD2I 
and CD24. Sixteen of 18 patients with oligoclonal disease had 
complete remission and the other two patients had partial 
remission with persistence of CNS disease. In some cases 
remissions occurred in patients who had not responded to 
reduced immunosuppression. Remission was not observed in 
seven patients who had monoclonal disease, despite the 
presence of the antigens on rumor cells. 
It has recendy been reponed in the lay press177 that transfer 
of generically altered heterologous lymphocytes has been 
successfully employed to eradicate a PTLD arising in a bone 
marrow transplant recipient. The patient, a woman, received 
an infusion of her brother's T lymphocytes which had been 
modified to contain a marker gene and a "suicide" gene. 
The transfused cells then attacked the tumor and in turn 
were eliminated by iatrogenic activation of the "suicide" 
gene. We eagerly await a detailed report of this novel 
therapeutic approach. 
In the absence of any appreciable response to treatment 
with conservative measures one must consider the use of 
antineoplastic radiotherapy, chemotherapy, or both. We have 
previously tabulated the use of chemotherapy and radio-
therapy in our patient population. IJ.7 We find that therumoIS 
often respond to such treatment and the major life-threaten-
ing complications are concurrent infection and rumor lysis 
syndrome. Late-arising monoclonal rumors which are either 
monomorphic or resemble Hodgkin's disease represent the 
most frequent scenarios under which chemotherapy is em-
ployed at our institution. Lien et al l78 reponed a case of 
monoclonal PTLD which arose 22 months following renal 
transplant and had a monomorphic appearance resembling 
Burkitt lymphoma. Complete remission was induced utiliz-
ingaProMACE-CytaBOM chemotherapeutic regimen. The 
patient became tolerant to her graft, and this was attributed to 
the effect of chemotherapy. However, since we have seen the 
same phenomenon in some of our patients treated with 
reduced immunosuppression. we mnsider the exact c:ause of 
the tolerance to be undefined. Barkholtetal179 described a case 
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of allograft-based P1ID which occurred ? months following 
liver transplant. Following two weeks of combination chemo-
therapy the patient refused additional drugs. The mass was 
then removed swgically and was found to be entirely necrotic. 
She has remained in complete remission during the three year 
follow-up. The rapid and complete response of this rumor to 
U suboptimal" chemotherapy suggests that protocols designed 
for standard lymphomas may be too aggressive in this disorder 
and that the optimal regimen remains to be defined. 
OTHER EBV-ASSOCIATED POSITRANSPUNT TUMORS 
T -cd.Ilymphoprollferations 
In one study of non-Hodgkin's lymphomas arising in 
non immunosuppressed patients, EBY was more frequently 
associated with peripheral T -cell lymphomas (10% of cases) 
than with B-celllymphomas.110 The virus can infect thymic 
T c-ells in vitro, but this has not yet been demonstrated in 
vivO. 181 We have recently observed a case of clonal T-cell 
lymphoproliferation in a patient who had a previous PTLD. 
The patient is currently under treatment for this condition 
and studies are currently underway to identify the EB virus-
infected cell type, i.e., T cell or other reactive cell (W u T et al, 
MS in preparation). In a separate reponed case EBV was 
localized to tumor cells of aT -cell lymphoma arising in a renal 
transplant patient.l82 Several examples of non-EBV-associ-
ated T -cell lymphomas in bone marrow or solid organ 
recipients have also been reponed.144.145 
Hodgkin's disease and "Recurrent" PTLDs 
Occasional cases of Hodgkin's disease in transplant recipi-
entshave been reponed. 18>18S In our series there have been twO 
such cases. In one patient, no EBV was found and there was 
a family history of leukemia. This patient received standard 
an tineoplastic therapy and ultimatdy died ofhis rumor. In the 
second case, the lesion was related to EBV.7 
This latter case is also interesting because it represents an 
example of recurrent EBV-rdated rumor in a transplant 
patient. This young female liver recipient developed a poly-
morphic PTLD following her transplant. Several B-cell clones 
were found, and at least two clones of EBY were present 
within the rumor. Immunosuppression was reduced and the 
rumor regressed. She remained well for about 2 years, when 
she presented with fever and night sweats. Evaluation showed 
involvemen[ of spleen, liver, and lymph nodes by a 
Iymphoproliferation most consistent with Hodgkin's disease. 
EBER staining showed the Reed-Sternberg-like cells to be 
uniformly positive for the virus. Clonal analysis again revealed 
a B-cell clone; however this clone was different from that 
found in the fim tumor. In addition, a separate clonal form of 
EBV was also found. The patient received chemotherapy for 
Hodgkin's disease and continues to do well without evidence 
of tumor 16 months after the initial diagnosis. 
This case shows that clinicallv recurrent rumor cannOt be 
assumed to represent pathologic recurrence of the original 
rumor in these parients. In different cases we h.zve seen 
histologically similar recurrence, clinical rccu.rrence of more 
aggressive appearing tumors, or clinical "recurrence" ofEBV-
associated tumors involving an encirdyciifrermtcell type (WU 
T et al. MS in preparation). It may be that EBV infection 
places these patients at risk for the development of a number 
of separate rumors, dependent upon the behavior of the 
individually infected cells within the immunosuppressed 
host. This concept may also underlie the spindle-cdl 
lesions described below. In passing it is noted that EBY-
positive Hodgkin's disease has been rarely observed as a 
sequel to non-Hodgkin's lymphoma in nonrmmuno-
compromised patients as well. l86 
Posttransplant Spindle-cell tumor 
Three cases of spindle-cell tumors within pediatric trans-
plant recipients have recently been observed within our series. 6 
One of these patients also had separate PTLD. EBV in situ 
hybridization was positive in all three cases. One patient has 
had her spindle-cell tumor controlled by excision. A second 
has had recurrent disease, and the third died of metastatic 
EBV-positive spindle-cell tumor. Molecular analysis of one 
case has shown clonal virus which appears to be integrated 
within the genome (Lee E et al, submitted). Actin and 
desmin stains suggest that the lesion represents a tumor of 
smooth muscle cells. It is of interest that spindle-cell 
tumors diagnosed as leiomyosarcomas have also been 
observed in AIDS patients. 187 In some cases this is associ-
ated with mycobacterial infection. No evidence of this 
agent was seen in any of our patients. The possibility of 
EBV panicipation in AIDS spindle-cell tumors, as well as 
in other reported cases of posttransplant leiomyosarcomal88 
and fibrosarcoma,189 remains to be explored. 
POSlTRANSPlANT LYMPHOMAS UNRElATED TO EBY 
Occasional EBY-negative lymphomas have been reported 
within transplant patients. These include T-cell lymph-
omas, 190-193 Hodgkin'sdisease,andnon-Hodgkin' slymphomas 
(personal observation). The relationship of these rumors to 
PTLDs remains problematic and at present it may be best to 
eva! uate and treat these as de novo malignancies. Nevenheless, 
we know of at least one case in which a P11..D which was 
negative for EBY by molecular analysis did regress following 
a reduction of immunosuppression. 
True lymphomas in solid organ transplant recipients most 
likdy derive from host lymphocytes. Rarely, a donor-derived 
lymphoma may occur. Meduri et al l9<4 reported a case ofEBV-
negativedonor-derivednon-Hodgkin'slymphomaarisingin 
a renal transplant patient. Antineoplastic therapy was success-
ful in eradicating disease for the 18 months of follow-up. 
THE SCID MOUSE IN THE STUDY OF 
EBV-ASSOCIATED LYMPHOMAGENESIS 
The development of the severely immunocompromised 
C.B-I? ICR scid/scid mouse (SCID)195 has provided a 
nonprimate model for the analysis of EBV-associated 
lymphomagenesis in human lymphoid cella..1!JI5.1" In this 
system, the inoculation of peripheral blood lymphocytes from 
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EBV-positive individuals precipitates the development of 
EBV-positive B-cell tumors.2OO The tumors may be mono-
clonal or oligoclonal, and generally display a phenotype 
similar to that of lymphoblastoid-cell lines with Type 3 
latencyK~oo Direct EBV infection of peripheral blood cells 
transferred into SCID mice from seronegative donors results 
in polyclonal tumors,lOI again mimicking a condition seen in 
some cases ofPTLD. 
SUMMARY 
Hypothetical pathogenesis of P11.Ds 
PTLD may be considered as an "opportunistic cancer" in 
which the immunodeficiency state of the host plays a key role 
in fostering the environment necessary for abnormal 
lymphoproliferation.::o2 The following discussion reflects our 
own current thoughts regarding events which may result in 
PTLD and its sequelae. Many of the individual steps have not 
been rigorously proved or disproved at this point in time. 
following transplantation and iatrogenic immunosup-
pression, the host:EBV equilibrium is shifted in favor of the 
virus. Most seronegative patients will become infected either 
via the graft or through natural means; seropositive patients 
will begin to shed higher levels of virus and may become 
secondarily superinfected via the graft. There is a "grace" 
period of approximately one month posmansplant before 
increased viral shedding begins. PTLD is almost never seen 
during this interval. In many cases infection continues to be 
silent whereas in rare individuals there is an overwhelming 
polyclonal proliferation of infected B lymphocytes. This is the 
parallel of infectious mononucleosis occurring in patients 
with a congenital defect in virus handling (X-linked 
Ivmphoproliferative disorder).::o3 It is possible that transplant 
patients with this presentation also sutter a defect in virus 
handling. In other cases excessive iatrogenic immunosuppres-
sion may paralyze their ability to respond to the infection. 
With CsA and FK506 regimens, individual tumors may 
occur within a matter of months following transplant. The 
short time of incubation suggests that these are less than fully 
developed malignancies. It may be that local events conspire 
[0 allow outgrowth of limited numbers of B-lymphocyte 
clones. Acytokine environment favoring B-lymphocytegrowth 
may be one factor and differential inhibition by the immuno-
suppressive drugs of calcium-dependent and -independent B-
cdl stimulation may be another. In addition, there is some 
evidence that CsA itself may inhibitapoptosiswithin B cells.204 
Since most patients do not develop PTLDs, an additional 
signa1(s) for B-cell stimulation may be required. Indeed, it is 
possible that the virus may simply serve to lower the threshold 
for B-cell activation and/or provide a survival advantage to 
rhese cells. The abilitY of individual cell clones to evade a 
weakened immune srs'tem may set inro playa Darwinian type 
()f competition in which the most rapidly proliferating cells 
with the least numberofantigenic targets predominate. In this 
regard, differences in host Hl.A types may determine the 
repertoire of viral antigens which are subject to attack. 
Since these rumors are a consequence of disordered physi-
ologic growth, restoration of a normal milieu may lead to a 
dying back of the process despite the presence or absence of 
clonal outgrowth. This is clinically evidenced as tumor regres-
sion in the faceofimmunomodulation. However, a subclinical 
latent infection of lymphoid and nonlymphoid cells may 
predispose to accumulation of individual cytogenetic ectOrs in 
rare cells and may lead to a fully malignant phenotype. This 
may be more likely to occur in those patients harboring larger 
numbers of the virus. Tumors arising from these cells would 
be expected to occur later in time than the majority ofIYTLDs 
and would be more likely to be resistant to immunomodulation 
therapy. 
In conclusion, the story of PTLDs is an evolving one. As 
more details of the biology ofEBV infection become under-
stood we will progress to a staging system for 1M which 
incorporates and explains both the infectious and neoplastic 
aspects of this host:parasite system. Until that time, the 
ongoing dissection of this family of lesions will continue to 
provide new surprises in the study ofvirus-associated human 
. . 
carCInogenesis. 
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